Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia
Open Access
- 1 October 2003
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 123 (2), 243-252
- https://doi.org/10.1046/j.1365-2141.2003.04610.x
Abstract
Summary. In children with acute myeloid leukaemia (AML), morphological and karyotypic studies cannot precisely assess response to treatment, and less than one‐third of patients have genetic markers for molecular studies of residual disease. We determined the usefulness of a four‐colour flow cytometric strategy developed in our laboratory to study residual disease. We first compared the immunophenotypes of AML cells obtained from 54 children at diagnosis with those of cells from 59 normal or regenerating bone marrow samples. Forty‐six of the 54 AML cases (85·2%) had immunophenotypes that allowed detection of 0·1–0·01% residual leukaemic cells. Of 230 bone marrow samples obtained from those 46 patients during and off treatment, 61 (26·5%) had ≥ 0·1% AML cells by flow cytometry. We found that core binding factor‐associated AML had a significantly better early treatment response. Mean (± standard error) 2‐year survival estimate was 33·1 ± 19·1% for patients with ≥ 0·1% AML cells by flow cytometry after induction therapy, but 72·1 ± 11·5% for those with < 0·1% AML cells (P = 0·022); overt recurrence of AML within the subsequent 6 months was significantly more likely in the former group. The assay described here holds promise for guiding the choice of post‐remission treatment options in children with AML.Keywords
This publication has 35 references indexed in Scilit:
- Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 TrialBlood, 2003
- Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemiaBlood, 2002
- Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemiaBlood, 2002
- Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcriptsLeukemia, 2002
- Advances in the immunological monitoring of childhood acute lymphoblastic leukaemiaBest Practice & Research Clinical Haematology, 2002
- Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemiaLeukemia, 2002
- Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratificationBlood, 2001
- A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer GroupBlood, 2001
- A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trialBritish Journal of Haematology, 1999
- Prediction of Relapse of Pediatric Acute Myeloid Leukemia by Use of Multidimensional Flow CytometryJNCI Journal of the National Cancer Institute, 1996